Pubfacts - Scientific Publication Data
  • Categories
  • Journals
  • ->
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Clinical outcome of hereditary breast cancer in the lithuanian population.

Authors:
Pavel Elsakov Juozas Kurtinaitis Valerij Ostapenko

Hered Cancer Clin Pract 2005 Apr 15;3(2):77-9. Epub 2005 Apr 15.

Vilnius University Institute of Oncology, Santariskiu 1, 2021 Vilnius, Lithuania.

Breast cancer family history has been known to be one of the main cancer risk factors. Members of high-risk families should be given recommendations which may improve prophylaxis, early diagnosis and treatment. Detection of high-risk families is possible by identification of mutations in cancer susceptibility genes like BRCA1 and BRCA2 as well as by family history showing breast and/or ovary cancer aggregation. In a group of 521 breast cancer patients we identified 26 patients with hereditary breast cancer who fulfilled the following criteria: one more relative with breast cancer, vertical transmission, at least one breast cancer patient affected at the age under 50 years. 8 patients of these developed second primary breast cancer. We also compared the frequency of hereditary cancers in stage I-III with the frequency of respective cancers with negative family history. Hereditary breast cancers were diagnosed less frequently in stage I and more frequently in stage II and III (RR = 0.49, RR = 1.39, RR = 1.62, respectively). Because of importance of family history as well as genetic testing for breast cancer susceptibility genes (BRCA1/2), it is necessary to create a nationwide network of hereditary cancer clinics for proper diagnosis, treatment, and prophylaxis of these patients.

Download full-text PDF

Source
http://dx.doi.org/10.1186/1897-4287-3-2-77DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837302PMC
April 2005

Publication Analysis

Top Keywords

breast cancer
32
family history
16
cancer
12
hereditary breast
12
breast
10
diagnosis treatment
8
high-risk families
8
cancer susceptibility
8
frequently stage
8
susceptibility genes
8
hereditary
5
162 family
4
fulfilled criteria
4
cancer fulfilled
4
patients hereditary
4
history well
4
breast and/or
4
cancer vertical
4
139 162
4
relative breast
4

Similar Publications

Follistatin-like 1 deficiency impairs T cell development to promote lung metastasis of triple negative breast cancer.

Authors:
Jie Ma Ying Yang Lulu Wang Xiaowei Jia Tao Lu Yiyan Zeng Li Liu Yan Gao

Aging (Albany NY) 2021 Feb 26;13. Epub 2021 Feb 26.

Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Department of Human Anatomy, School of Basic Medical Sciences, Capital Medical University, Beijing, China.

Our study aims to detect the underlying mechanism of the suppressive effect of Follistatin-like 1 (FSTL1) on lung metastasis of triple negative breast cancer (TNBC). We found that FSTL1 had no effect on the proliferation and metastasis of 4T1 cells in , while in the tumor-bearing Fstl1 heterozygous () mice, the number of anti-tumor T lymphocytes in the lung was significantly reduced with the increase in lung metastasis. Impaired development of T cells can cause dysfunction of adaptive immune system, which promotes cancer metastasis. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis.

Authors:
R Caparica M Bruzzone E Agostinetto C De Angelis  Fêde M Ceppi E de Azambuja

ESMO Open 2021 Feb 24;6(2):100066. Epub 2021 Feb 24.

Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.

Background: Preclinical and retrospective studies suggest that beta-blockers are active against breast cancer. We carried out a systematic review and meta-analysis to assess the impact of beta-blockers on the outcomes of patients with early-stage breast cancer.

Methods: A systematic literature search was performed to identify studies comparing outcomes of patients with early-stage breast cancer according to beta-blocker use (yes versus no). Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8.

Authors:
Yunjiao Zhang Xiaowan Huang Liansheng Wang Cong Cao Hao Zhang Pengfei Wei He Ding Yang Song Ziying Chen Jieying Qian Suqin Zhong Zefeng Liu Meimei Wang Wenbin Zhang Wenwei Jiang Jie Zeng Guangyu Yao Long-Ping Wen

Biomaterials 2021 Feb 14;271:120720. Epub 2021 Feb 14.

Department of Cardiology, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. Electronic address:

Point mutations within the DNA-binding domain of the TP53 gene occur in a significant percentage of human cancer, leading to cellular accumulation of highly stabilized mutant p53 proteins (mutp53) with tumor-promoting properties. Depletion of mutp53, through inducing either autophagic or proteasomal degradation, is an attractive strategy for the therapy of p53-mutated cancer, but the currently-known degradation inducers, almost exclusively small molecules, are inadequate. Here we show that pH-responsive zeolitic imidazolate framework-8 (ZIF-8) offers a novel solution to mutp53 degradation. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

One-step synthesis of multifunctional nanoparticles for CT/PA imaging guided breast cancer photothermal therapy.

Authors:
Liwen Fu Shuguang Yang Shichao Jiang Xiaojun Zhou Zhou Sha Chuanglong He

Colloids Surf B Biointerfaces 2021 Feb 18;201:111630. Epub 2021 Feb 18.

State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, China. Electronic address:

Advances in nanotheranostics have promoted the development of precision medicine, which has great potential as a weapon for clinical diagnosis and therapy of tumors. However, the combination of three functional principle components (imaging probes, therapeutic agents and surface coating) in traditional theranostic system is difficult to be achieved in only one step, while undergoing multiple synthesis procedures, time-consuming process and unknown toxicity. Herein, we fabricated iodinated polyaniline (LC@I-PANi) nanoparticles via a facile one-step synthesis approach integrating chemical oxidative polymerization and iodine-doping process for computed tomography (CT) imaging and photoacoustic (PA) imaging-guided photothermal therapy (PTT). Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Identification of a new natural biflavonoids against breast cancer cells induced ferroptosis via the mitochondrial pathway.

Authors:
Yang Xie Xi Zhou Jing Li Xiao-Chang Yao Wan-Li Liu Feng-Hua Kang Zhen-Xing Zou Kang-Ping Xu Ping-Sheng Xu Gui-Shan Tan

Bioorg Chem 2021 Feb 17;109:104744. Epub 2021 Feb 17.

Phase I Clinical Trial Center, Xiangya Hospital, Central South University, Changsha 410008, PR China. Electronic address:

Breast cancer is one of the major malignant tumors in females, and currently, recurrence and metastasis are the main obstacles preventing effective breast cancer treatment. Biflavonoids of secondary metabolites from plants are excellent anticancer agents to fight sensitive and resistant breast cancer cell lines. In this study, six C-3'-C-6″ biflavonoids, including one new robustaflavone A (1, RF-A) and five known robustaflavone derivatives (2-6), were isolated from Selaginella trichoclada for the first time. Read More

View Article and Full-Text PDF
February 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap